Close
Smartlab Europe
Inizio Ignite

Intec Pharma Announces New Research Collaboration Agreement with MSD

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced that it plans to invest...
- Advertisement -
Smart Lab Europe

Intec Pharma Ltd. announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential.

“We are very excited to continue to work with MSD,” said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. “This new agreement builds upon the relationship we have enjoyed in prior research and allows the companies to leverage their combined experience in delivery.”

About Intec Pharma Ltd.

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.

Smart Lab Europe

Latest stories

Related stories

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced that it plans to invest...

Precision Cellular Analysis Powering the Next Generation

Biopharmaceutical innovation increasingly depends on understanding biology at the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »